Gibbs Wealth Management »

Halozyme Therapeutics shares owned by Gibbs Wealth Management

Quarter-by-quarter ownership of Halozyme Therapeutics (HALO) shares owned by Gibbs Wealth Management from 13F filings

Historical chart of Gibbs Wealth Management investment in Halozyme Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Halozyme Therapeutics held by Gibbs Wealth Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Halozyme Therapeutics by Gibbs Wealth Management

Quarter filed Position value Share count Share price at filing
2025-09-30 $228k 3.1k 73.34
2025-06-30 $222k 4.3k 52.02
2025-03-31 $225k 3.5k 63.81

More positions owned by Gibbs Wealth Management

Spdr Series Trust Prtflo S&p500 Gw (SPYG)
Spdr Index Shs Fds Portfolio Devlpd (SPDW)
Ishares Tr Us Treas Bd Etf (GOVT)
Ishares Tr 0-5yr Hi Yl Cp (SHYG)
Northern Lts Fd Tr Iv Main Sectr Rotn (SECT)
Spdr Series Trust Prtflo S&p500 Vl (SPYV)
Spdr Series Trust Port Mtg Bk Etf (SPMB)
Vanguard Scottsdale Fds Int-term Corp (VCIT)
Microsoft Corporation (MSFT)
Spdr Series Trust Portfolio Ln Tsr (SPTL)
NVIDIA Corporation (NVDA)
Oracle Corporation (ORCL)
Amazon (AMZN)
Spdr Series Trust Bloomberg 1-3 Mo (BIL)
Spdr Series Trust Portfolio S&p600 (SPSM)

View all positions for Gibbs Wealth Management

Top funds holding Halozyme Therapeutics

BlackRock
Vanguard Group
State Street Corporation
Arrowstreet Capital, Limited Partnership
Invesco
UBS Group
Snyder Capital Management
D. E. Shaw & Co
Geode Capital Management
Dimensional Fund Advisors
Alliancebernstein
Morgan Stanley
Macquarie Group
Federated Investors
Congress Asset Management

View all funds holding Halozyme Therapeutics